Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Catalyst Pharmaceutical Partners, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Catalyst Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”) (NASDAQ: CPRX) of the December 24, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Catalyst and certain executives.
A complaint has been filed on behalf of all persons who purchased Catalyst securities between October 31, 2012 and October 18, 2013 (the “Class Period”).
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that throughout the Class Period Catalyst issued false and/or misleading statements and failed to disclose material facts regarding Firdapse, a drug candidate that the Company purported would be used to treat Lambert-Eaton Myasthenic Syndrome (“LEMS”).
In fact, prior to the market open on October 18, 2013, an article in The Street revealed that another pharmaceutical company has provided an equivalent drug free of charge for the past 20 years.
Following this news, the Company’s stock declined $0.71 per share, or over 27%, to close at $1.90 per share on October 18, 2013.
If you invested in Catalyst stock or options between October 31, 2012 and October 18, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalyst’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.